There are currently 474 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Recruiting
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemother... Read More
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
04/10/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Register for Updates
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
NCT05489705
Recruiting
The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The registry study also provide a real-world understanding of the current obstructive HCM patient population, treatment patterns, and clinical relevant outcomes for patients with symptomatic obstructive HCM in the US.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: St. Luke's Mid-America Heart Institute, Kansas City, Missouri
Conditions: Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Truman Medical Centers, Kansas City, Missouri +3 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Childhood Malignant Neoplasm
Register for Updates
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Recruiting
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Gender:
All
Ages:
99 years and below
Trial Updated:
04/05/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Childhood Malignant Neoplasm
Register for Updates
Social Determinants and a Diabetes Prevention Program Tailored for African Americans
NCT05301413
Recruiting
African Americans (AAs) have rates of diabetes mellitus (DM) twice that of Whites and are disproportionately affected by leading risk factors for DM - obesity and low-income. A critical strategy in the battle against DM is the Diabetes Prevention Program (DPP), an evidence-based intervention that significantly delays or prevents Type 2 diabetes through the promotion of diet change, exercise and modest weight loss. However, weight loss from the DPP among AAs is about half that of White participan... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: University Health, Kansas City, Missouri +1 locations
Conditions: PreDiabetes, Overweight and Obesity
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
All
Ages:
31 years and below
Trial Updated:
04/04/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Neuroblastoma
Register for Updates
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
All
Ages:
21 years and below
Trial Updated:
04/04/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Medulloblastoma
Register for Updates
PV Loop & Coarctation Study
NCT05362721
Recruiting
Coarctation of the aorta accounts for 4-7% of all congenital heart disease. While stent therapy, when feasible, is the standard of care for coarctation, it may not completely improve the work (and afterload) of the heart due to its effects on the elasticity of the aorta. This study will provide the information needed to understand the effects of current management on the cardiac mechanics and work.
Gender:
All
Ages:
6 years and above
Trial Updated:
04/04/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Coarctation of Aorta
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
All
Ages:
22 years and below
Trial Updated:
04/04/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Neuroblastoma
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/04/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Neuroblastoma
Register for Updates
Laryngeal Mask Airway in Laparoscopic Hernia Repair
NCT06023394
Recruiting
This prospective randomized study will evaluate the effectiveness of laryngeal mask airway (LMA) versus endotracheal intubation (ETT) for patients undergoing laparoscopic inguinal hernia at CMH.
Gender:
All
Ages:
Between 12 months and 8 years
Trial Updated:
04/03/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Inguinal Hernia, Inguinal Hernia, Indirect, Inguinal Hernia Bilateral, Inguinal Hernia Unilateral
Register for Updates